2 assets in Endometrioid Tumor

Therapeutic assets addressing Endometrioid Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pasifolate Exatecan Endometrioid Tumor	Elucida Oncology	P1/2	CCC (48)
lyl797 Endometrioid Tumor	Lyell Immunopharma, Inc.	P1	CC (43)